Inicio / Hematología / Abstracts de hematología / Outcomes in patients treated…

Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study

0 / 5 (0 votos)
Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study

The Lancet Haematology

Fecha de publicación: Mayo de 2021

DOI: https://doi.org/10.1016/S2352-3026(21)00060-0

Autores: Prof Élie Azoulay, PhD , Pedro Castro, MD, Adel Maamar, MD, Victoria Metaxa, PhD, Alice Gallo de Moraes, MD, Louis Voigt, MD, Florent Wallet, MD, Prof Kada Klouche, PhD, Muriel Picard, MD, Anne-Sophie Moreau, MD, Andry Van De Louw, MD, Amélie Seguin, MD, Djamel Mokart, PhD, Sanjay Chawla, MD, Julien Leroy, RN, Boris Böll, PhD, Nahema Issa, MD, Prof Bruno Levy, PhD, Pleun Hemelaar, MSc, Sara Fernandez, MD, Laveena Munshi, MD,Prof Philippe Bauer, PhD, Prof Peter Schellongowski, PhD, Prof Michael Joannidis, PhD Gabriel Moreno-Gonzalez, MD, Prof Gennadii Galstian, PhD, Prof Michael Darmon, PhD, Sandrine Valade, MD

Background: Chimeric antigen receptor (CAR) T-cell therapy can induce side-effects such as cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome (ICANS), which often require intensive care unit admission. The aim of this study was to describe management of critically ill CAR T-cell recipients in intensive care. Methods: This international, multicentre, observational cohort study was done in 21 intensive care units in France, Spain, the USA, the UK, Russia, Canada, Germany, and Austria. Eligible patients were aged 18 years or older; had received CAR T-cell therapy in the past 30 days; and had been admitted to intensive care for any reason. Investigators retrospectively included patients admitted between Feb 1, 2018, and Feb 1, 2019, and prospectively included patients admitted between March 1, 2019, and Feb 1, 2020. Demographic, clinical, laboratory, treatment, and outcome data were extracted from medical records. The primary endpoint was 90-day mortality. Factors associated with mortality were identified using a Cox proportional hazard model.

Leer más

Comentarios

Para dejar un comentario antes debes iniciar sesión:

¿No tienes una cuenta?

Regístrate a través de éste enlace.